Related Experiment Videos
Aromatase inhibitor-associated bone loss: clinical considerations
Shubham Pant1, Charles L Shapiro
1The Comprehensive Breast Health Services, Arthur G. James Cancer Hospital and Richard J. Solve Research Institute, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.
Drugs
|December 20, 2008
Summary
Aromatase inhibitors treat breast cancer but cause bone loss. Lifestyle changes and bisphosphonates help prevent this bone loss, though optimal bisphosphonate use is still being studied.
Area of Science:
- Oncology
- Endocrinology
- Bone Metabolism
Background:
- Aromatase inhibitors (AIs) are a standard treatment for postmenopausal women with estrogen-responsive breast cancer.
- AI therapy inhibits the aromatase enzyme, leading to decreased endogenous estrogen levels.
- This estrogen reduction is associated with significant bone loss and an increased risk of fractures.
Purpose of the Study:
- To review the screening and prevention strategies for AI-induced bone loss.
- To discuss the role of lifestyle modifications and bisphosphonates in managing bone health in patients on AIs.
- To highlight the current gaps in knowledge regarding optimal bisphosphonate therapy for AI-induced bone loss.
Main Methods:
- Review of current clinical guidelines and literature on AI-induced bone loss.
- Analysis of the mechanisms of bone loss associated with AI therapy.
- Evaluation of the efficacy of bisphosphonates in mitigating AI-induced bone loss.
Main Results:
- Screening and prevention of AI-induced bone loss align with postmenopausal osteoporosis recommendations.
- Lifestyle interventions including physical activity, weight-bearing exercise, smoking cessation, and adequate calcium/vitamin D intake are crucial.
- Bisphosphonates are effective in reducing bone loss in women treated with AIs.
Conclusions:
- AI-induced bone loss is a significant concern requiring proactive management.
- Lifestyle modifications and bisphosphonate therapy are key components of prevention and treatment.
- Further research is needed to define the optimal dosing, schedule, and duration of bisphosphonate treatment for AI-induced bone loss.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...